Tareno Health­care Funds Monthly Report, October 2026

Health­care stocks rose 9.9% in October, signi­fi­cantly outper­forming the global stock market. A rotation into more defen­sive sectors and solid quarterly results supported this perfor­mance. Our monthly review highlights the key industry trends as well as the perfor­mance of the Tareno Sustainable Health­care Fund and the Tareno Impact Health­care Fund.

Market review

The health­care sector rose 9.9% in October, signi­fi­cantly outper­forming global equities, which fell 0.8%. The strong rally also put the sector back in the lead year-to-date: With a gain of 15.6%, it outper­formed the MSCI World (+10.9%). This perfor­mance was supported by a prono­unced rotation away from AI and techno­logy stocks. Investors incre­a­singly viewed health­care as a poten­tial benefi­ciary of both political develo­p­ments and the adoption of AI. Renewed discus­sions about expan­ding govern­ment-funded health­care bolstered senti­ment ahead of the U.S. elections. Growing aware­ness of AI-driven produc­ti­vity gains, parti­cu­larly in drug develo­p­ment and diagno­stics, further enhanced the sector’s long-term appeal. Q3 earnings also supported stock prices. So far, 50% of the index compa­nies have reported; 71% exceeded revenue expec­ta­tions and 83% beat EPS estimates. The magni­tude of the earnings surprises was largely in line with that of the second quarter. The results confirmed existing trends: Higher biopharma spending benefited Life Sciences Tools & Services. Lower utilization rates for more complex proce­dures weighed on MedTech and hospi­tals but benefited managed-care insurers thanks to better-than-expected medical loss ratios. On the M&A front, there were several transac­tions excee­ding USD 1 billion, inclu­ding the acqui­si­tion of Option Care by private-equity investors and McKesson for USD 5.8 billion, the acqui­si­tion of Surgery Partners by Health­Span for USD 5.7 billion, the acqui­si­tion of Pacira Biosci­ences by Viatris for USD 1.7 billion, and the acqui­si­tion of Silence Thera­peu­tics by Merck KGaA for USD 1.3 billion.

The pharmaceu­tical sector rose 11.4% and was among the main benefi­ci­a­ries of the rotation from AI and techno­logy stocks into more defen­sive sectors. Strong Q3 results from major pharmaceu­tical compa­nies provided additional support for the sector’s perfor­mance. Clinical updates from the European Society for Medical Oncology (ESMO) confe­rence also influenced stock prices, though reactions within the sector were mixed.

Provi­ders & Services rose by 10.4%. Drug distri­bu­tors (+13.6%) benefited from the flight to defen­sive stocks. McKesson and Cardinal Health received an additional boost from the exten­sion of their drug distri­bu­tion contracts with CVS through 2032. Managed care rose by 10.2%, supported by more favorable trends in treat­ment costs and expec­ta­tions of a more favorable health­care policy environ­ment follo­wing the U.S. midterm elections. Medicare Advan­tage star ratings also influenced perfor­mance, with Humana emerging as the clear winner. Facili­ties rose 9.4% despite lower utilization for more complex proce­dures, as valua­tions benefited from expected policy changes follo­wing the U.S. elections. Services rose 8.4%, led by high single-digit to double-digit price gains in lab stocks.

Biotech (+9.9%) performed similarly to the pharmaceu­tical sector. Large compa­nies benefited from defen­sive investor positio­ning, solid Q3 results, and clinical updates surroun­ding ESMO 2026. Highlights included encou­ra­ging data on Genmab’s petosem­tamab in combi­na­tion with Keytruda for head and neck cancer, as well as on Amgen’s imdelltra as a first-line mainten­ance therapy for small-cell lung cancer.

MedTech (+7.6%) rebounded in October despite ongoing weakness among ortho­pedic compa­nies and disap­poin­ting Q3 results from several industry leaders. Nevert­heless, numerous large-cap stocks rose from their lows follo­wing the quarterly earnings reports. Investors incre­a­singly viewed earnings forecasts as less risky and considered valua­tions attrac­tive relative to the broader health­care sector. The markets for dental products and hearing aids presented a mixed picture, while funda­men­tals remained intact. Hospital equip­ment suppliers performed well and signaled solid invest­ment demand.

Life Sciences Tools & Services rose 4.1% in October and took a breather follo­wing the strong rally of the previous months. Q3 results remained encou­ra­ging: Danaher and Thermo Fisher reported robust biopharma demand and stable spending in the Academia & Govern­ment segment. Positive results from CROs also bolstered confi­dence in a broad-based industry recovery. On the last trading day of October, however, the subsector lost 3%, weighed down by Illumina’s quarterly report, which failed to meet high investor expec­ta­tions.

Tareno Sustainable Health­care Fund Review

Last month, we neither estab­lished new positions nor closed existing ones. In October, the fund posted a return of 8.3%, while the bench­mark index rose 9.9%.

The largest positive drivers of attri­bu­tion relative to the index were:

  • Genmab ( +42 bps): The stock rose 67% in October, buoyed by positive Phase 3 results for petosem­tamab in head and neck cancer, Rina‑S in ovarian cancer, and epcori­tamab in lymphomas.
  • Roche ( +13 bps): The stock benefited from the strength of the pharmaceu­tical sector, solid Q3 results, and positive pipeline data on CT-996 (an oral GLP‑1 agonist), Sefaxersen, and Divarasib (presented at ESMO).
  • Illumina ( +12 bps): Not invested.

The largest negative drivers of attri­bu­tion relative to the index were:

  • Eli Lilly ( -42 bps): The stock rose 23% in October. We are under­weight relative to the index.
  • Alnylam ( -32 bps): The stock declined follo­wing its Q3 results. Restric­tions on insurance coverage, delays in the pipeline, and expec­ta­tions that TTR’s annual revenue would be at the lower end of the forecast weighed on senti­ment.
  • Dexcom ( -28 bps): Concerns about CGM market growth follo­wing weaker-than-expected results from compe­titor Abbott weighed on the stock. Solid Q3 results and positive clinical data from the CONNECT study parti­ally offset the weakness.

Tareno Impact Health­care Fund Review

Last month, we neither estab­lished new positions nor closed any existing ones. In October, the fund generated a return of 6.1%.

The largest positive contri­bu­tors were:

  • Eli Lilly ( +76 bps): The overall strength of the pharmaceu­tical sector, regula­tory progress (a positive recom­men­da­tion from the EU CHMP for Foundayo), and better-than-expected Q3 results drove the stock higher.
  • Teladoc ( +73 bps): Strong Q3 results.
  • Sandoz ( +61 bps): The stock rose in the wake of the Capital Markets Day and continued its upward trend after­ward. The Q3 revenue figures released on October 28 were mixed. Overall, the stock gained 16% in October.

The largest negative contri­bu­tors were:

  • Axsome (-69 bps): No specific news. Mixed signals regar­ding the progress of Auvelity’s (ADA) U.S. market launch, as well as several downward revisions to broker estimates ahead of the quarterly earnings report.
  • Hypera (-61 bps): No company-specific news. The stock fell sharply amid a broad sell-off on the Brazi­lian stock market follo­wing Presi­dent Lula’s reelec­tion. Concerns about the fiscal outlook triggered a sharp revalua­tion of domestic stocks.
  • BioNTech (-21 bps): Disap­poin­ting Phase 2/3 results for BNT113 in head and neck cancer. The primary endpoint for progres­sion-free survival was not met.

Subscribe to the Health­care Newsletter

Sign up for our newsletter and receive regular updates on the Tareno Health­care Funds directly via email. Benefit from the fund manage­ment team’s insights on market develo­p­ments, industry trends, and the positio­ning of the two health­care strate­gies.

Publi­ca­tions

Tareno Health­care Funds

Disclaimer

This document has been prepared for marke­ting and infor­ma­tional purposes and does not consti­tute an offer or a solici­ta­tion to subscribe to, buy, or sell shares of this invest­ment fund. It does not consti­tute invest­ment advice. Only the current fund documents (in parti­cular, the prospectus and KID) are exclu­si­vely autho­ri­ta­tive. Past perfor­mance is not a reliable indicator of future results.

Images: Marijke Vosmeer, Luzia Hunziker, Jürg Kaufmann, Istock, Unsplash / Graphics: Tareno AG / Bloom­berg